HYPERCOAGULATION AND VIRAL INFECTION: RATIONALE OF THE USE OF ANTI-THROMBOTIC THERAPIES IN CORONAVIRUS-19 DISEASE

The key-events in the clinical evolution of Covid-19 disease are the coagulation disorders. Starting from the evidences of the literature and analyzing the mechanisms involved in the coagulopative process following Covid-19 infection, it is confirmed that Antithrombotic Therapies, associated withAnti-Inflammatory Drugscommonly used in the hospital, often avoid the access of the patients in Intensive Care for assisted ventilation with improved disease prognosis. To avoid the progression of the disease in severe respiratory insufficiency it is of fundamental importance to protect the blood vessels with Antithrombotic Therapy. The administration of heparins (standard orlow molecular weight heparin) improves the prognosis of the disease by reducing the damage of pulmonary thromboembolism, myocardial infarction, heart failure, ischemic stroke and kidney damage avoiding the poor prognosis of the infection.